ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells

BACKGROUND: Platinum drugs, including cisplatin, are a frontline therapeutic in ovarian cancer treatment and acquired resistance to these agents is a major contributor to ovarian cancer morbidity and mortality. In this study a novel glycosylation-dependent mechanism for cisplatin resistance is descr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Schultz, Matthew J, Swindall, Amanda F, Wright, John W, Sztul, Elizabeth S, Landen, Charles N, Bellis, Susan L
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3637436/
https://ncbi.nlm.nih.gov/pubmed/23578204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1757-2215-6-25
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares